Lifeward Ltd.

Lifeward Ltd. makes the ReWalk personal exoskeleton, a wearable powered device for people with spinal cord injury, and sells AlterG anti-gravity treadmills, the ReStore exo-suit and MyoCycle FES cycles to rehabilitation clinics. The company was incorporated in Israel in 2001, changed its name from ReWalk Robotics Ltd. on September 10, 2024, and trades on the Nasdaq Capital Market as LFWD. Its principal executive office is 2 Cabot Road, Hudson, Massachusetts, with offices in Yokneam Illit, Israel and Berlin. Mark Grant became CEO on May 19, 2025 and Almog Adar CFO on August 13, 2025.

Scale

Per its 10-K, revenue was $22.0 million in 2025 against $25.7 million in 2024. The company had 81 employees at December 31, 2025 (46 in the US, 25 in Israel, 10 in Europe), $2.2 million in cash, an accumulated deficit of about $284.7 million, and disclosed substantial doubt about its ability to continue as a going concern. AlterG, acquired in August 2023 for about $19 million in cash, has an installed base of more than 6,000 units.

Regulatory and reimbursement

The ReWalk 7 received FDA 510(k) clearance in March 2025 and CE Mark in September 2025. Medicare pays for personal exoskeletons under HCPCS code K1007 in the brace benefit category, at a lump-sum fee schedule amount of $91,032 effective April 1, 2024. The first commercial Medicare Advantage payment came September 9, 2025; by February 17, 2026 Aetna, UnitedHealthcare and Humana had issued prior authorizations.

Financing

On January 13, 2026 Lifeward agreed a deal giving Oramed Pharmaceuticals up to 49.99 percent of its equity and 4 percent of ReWalk net sales for up to 10 years, with access to up to about $47 million of capital. Shareholders approved it on March 12, 2026.